Argenx (ARGX) 2025 Net Product Sales Rise 90% to $4.2B as First Annual Profit Reached

Argenx SE (NASDAQ:ARGX) is one of the best NASDAQ stocks to buy according to hedge funds. On February 26, Argenx reported earnings for 2025, achieving its first year of annual operating profitability with $4.2 billion in net product sales, a 90% increase over 2024. This growth was fueled by the global adoption of VYVGART, which reached 19,000 patients by year-end. Management highlighted the successful launch of the prefilled syringe as a significant driver of demand, contributing to a surge of 1,000 new prescribers since its introduction.

In clinical developments, the company announced positive results from the Phase III ADAPT-OCULUS study for ocular Myasthenia Gravis/MG. The study met its primary endpoint, showing statistically significant improvements in patient-reported ocular symptoms like double vision and drooping eyelids. With a PDUFA date for seronegative MG set for May 10, and plans to file for the ocular MG indication, Argenx aims to establish the broadest MG label in the industry, targeting an addressable US population of ~60,000 patients.

For 2026, Argenx SE (NASDAQ:ARGX) expects operating expenses to grow in alignment with revenue expansion as it scales its commercial infrastructure and advances its immunology pipeline. Beyond MG, the company is focused on the ongoing launch in CIDP and upcoming readouts for Sjögren’s disease and myositis.

Grail Inc.'s Galleri cancer test screening kit. Photo from Grail website

Argenx SE (NASDAQ:ARGX) is a commercial-stage biopharma company that develops therapies for autoimmune diseases in the US, Japan, China, the Netherlands, and internationally.